The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator, Main Campus
Phone: 314-747-8694 Fax: 314-362-6080
sefarris@wustl.edu

Justin Stout, Clinical Research Coordinator, Main Campus
Phone: 314-273-3737 Fax: 314-362-6080
justinjstout@wustl.edu

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator, All sites
Phone: 314-362-8171 Fax: 314-362-6080
mtabacchi@wustl.edu

Milan Anadkat, MD, Director, Clinical Trials Unit
manadkat@wustl.edu 

Currently Enrolling Trials

Dr. Milan Anadkat- (COH)

A study to test whether BI 655130 (Spesolimab-IL-36) prevents flare-ups in patients with Generalized Pustular Psoriasis

ClinicalTrials.gov Identifier: NCT04399837

A pragmatic study of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis (Short Title: Light Treatment Effectiveness (LITE) Study)

ClinicalTrials.gov Identifier: NCT03726489

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 (CXCR1, 2) (Intravenous) in Adults with Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov Identifier: NCT04493502

A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial with a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 (oral P2X7) in Patients with Hidradenitis Suppurativa

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 (SQ, IL-36) in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy

ClinicalTrials.gov Identifier: NCT04697069

The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields

ClinicalTrials.gov Identifier: NCT04469075

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

ClinicalTrials.gov Identifier: NCT04501666

Dr. Amy Musiek- (COH)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 (Deucravacitinib; TYK2 inhibitor) in Subjects with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis

ClinicalTrials.gov Identifier: NCT03181893

A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)

ClinicalTrials.gov Identifier: NCT02811783